तुलना करने के लिए मीट्रिक्स | ERAS | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधERASपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −24.0x | −6.4x | −0.4x | |
PEG अनुपात | 0.38 | −0.04 | 0.00 | |
क़ीमत/बुक | 16.9x | 2.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 60.1x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 17.4% | 94.0% | 53.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | −3.0% | 9.0% | अनलॉक करें |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.